$ATNM “Lion Stock Alerts” Promoter Rank: 19/21 Actinium Pharmaceuticals, Inc. Newsletter 7:36:35 AM March 24, 2021

on March 24, 2021 Newsletters and Tags: , , , , , , , , , , with 0 comments

Overall Perfomance for "Lion Stock Alerts"

The following three charts can be used by potential investors to gauge the performance of "Lion Stock Alerts":

10%

1 out of 10 campaigns closed down on first day

40%

4 out of 10 campaigns closed up on first day

50%

5 out of 10 campaigns had no net effect

ATNM Promotional Newsletter

The following is a newsletter released by "Lion Stock Alerts" promoting Actinium Pharmaceuticals, Inc.

Caution

The following newsletter has not been verified for accuracy or completeness.

LionStockAlerts

Don't Want Anymore Emails

Hello

New Alert Actinium Pharmaceuticals, Inc. NYSE ATNM

ATNM is a clinical-stage biopharmaceutical company developing ARCs or Antibody Radiation-Conjugates, which combine the targeting ability of antibodies with the cell killing ability of radiation.

The company is focused on three primary areas

Bone Marrow Transplant BMT
Multiple Myeloma
Acute Myeloid Leukemia AML

A bone marrow transplant is a procedure that infuses healthy blood-forming stem cells into your body to replace your damaged or diseased bone marrow.

Doctors use these transplants to treat people with certain diseases, such as Multiple Myeloma and Leukemia.

Sadly, multiple myeloma is the second most common blood cancer diagnosis.

The companys lead application for ARCs is targeted conditioning, which is intended to selectively deplete a patient's disease or cancer cells and certain immune cells.

In addition, the company is developing a multi-disease, multi-target pipeline of clinical-stage ARCs.

Plus, underpinning the companys clinical programs is their proprietary AWE Antibody Warhead Enabling technology platform.

As the company recently explained

The intellectual property encompassing Actinium's AWE technology platform covers its gold standard linker technology, methods of ARC manufacture in addition to methods of use for ARCs in multiple diseases, including indication, dose and scheduling, radionuclide warhead, and therapeutic combinations.

Actinium's AWE technology patent portfolio includes 30 patent families comprised of over 135 issued or pending global patent applications, of which 10 are issued and 24 pending in the United States.

Over the past few months, the company has announced multiple developments that could position it for further growth.

In December, the company announced

Actinium Announces Successful Pre-Planned Ad Hoc Interim Analysis of Phase 3 SIERRA trial

Here are the highlights from this press release

100% rate of BMT and engraftment in patients receiving therapeutic dose of Iomab-B and lower rates of sepsis and sepsis related Grade 3 adverse events compared to patients receiving salvage therapies at 75% enrollment recently highlighted in oral presentations at ASH 2020 Annual Meeting
Independent Data Monitoring Committee recommends SIERRA continue as planned to full enrollment of 150 patients trial is currently over 75% enrolled
SIERRA trial remains the only randomized Phase 3 trial to offer potentially curative bone marrow transplant as an option for patients with active relapsed or refractory AML

In January, the company announced

Actinium and Astellas Announce Research Collaboration Focused on Novel Actinium-225 Based Targeted Radiotherapies

Here are some of the companys comments from this press release

Sandesh Seth, Chairman and Chief Executive Officer of Actinium, added, Through our development efforts, Actinium has established itself as a leader in the field of Actinium-225 based targeted radiotherapies. We have amassed the most experience treating patients with Actinium-225 via our CD33 program's several Actimab-A trials and have gained important insights in developing targeted radiotherapies through the execution of the Actimab-A and also SIERRA Phase 3 pivotal trial for our lead asset, Iomab-B. This expertise and experience with radiopharmaceuticals has been invaluable to us and we believe will also be to Astellas in this collaboration. As Iomab-B and Actimab-A advance in the clinic with multiple clinical milestones upcoming from each of our trials, we look forward to executing this collaboration and furthering the field of targeted radiotherapy with Astellas.

Over the past few months, the company has participated in multiple conferences

Actinium Highlights Presence at Targeted Radiopharmaceuticals Summit

Actinium to Participate in a Fireside Chat at the B. Riley Oncology Investor Conference
Actinium Announces Participation in BIO CEO Investor Digital Conference
Actinium Showcases Targeted Conditioning Program with 2 Oral Presentations Highlighting Iomab-B and Pivotal Phase 3 SIERRA Trial at 2021 Transplantation Cellular Therapy Annual Meeting
Actinium Announces Participation in H.C. Wainwright Global Life Sciences Conference

In March, the company announced

Actinium Announces Appointment of Mark Kubik, MBA as Chief Business Officer

Here are the highlights from this press release

Mr. Kubik joins Actinium with over 25 years of experience in transformative and award-winning BD and MA transactions
Proven deal making abilities in the empowered antibody, biologics and gene therapy fields strongly suited to Actinium's AWE technology platform and Antibody Radiation Conjugates for targeted conditioning

In addition, recently the company announced

Actinium to Highlight Expansion of Targeted Conditioning Portfolio at AACR with Next-Generation Actinium-225-Based CD45 Targeting ARC

Here are the highlights from this press release

Positive preclinical data support continued development with strong potential in bone marrow transplant, adoptive cell therapy and gene therapy applications
Potent alpha emitter Actinium-225 targeted to CD45 cells demonstrates positive biodistribution profile and dose-dependent conditioning capabilities

Plus, just this morning, the company announced

Actinium Announces Initiation of Patient Enrollment in Iomab-ACT Trial for Targeted Conditioning Prior to CD19 CAR T-Cell Therapy

ATNM could present increased growth potential.

Make sure to do your own due diligence.

Sources , , , , , , , , , , , , , ,

Happy Trading

LionStockAlerts

Note We encourage all traders and investors to develop personal trading rules that you can follow and that work for you. Always protect your downside and note that we alert extremely volatile short-term opportunities. Before investing in securities, you should always consult with your financial, tax and legal advisor and never invest money you cannot afford to lose.

--------------------------

DISCLAIMER

You should read and understand this disclaimer in its entirety before joining the website or emailblog list of LionStockAlerts.com the Publisher. The information collectively the Advertisement disseminated by email, text or other method by the Publisher including this publication is a paid commercial advertisement and should not be relied upon for making an investment decision or any other purpose. The Publisher is engaged in the business of marketing and advertising the securities of publicly traded companies in exchange for compensation. The track record, gains, upside, andor losses mentioned in the Advertisement, if any, should not be considered as true or accurate or be the basis for an investment. The Publisher does not verify the accuracy or completeness of any information included in the Advertisement. While the Publisher does not charge for the SMS service, standard carrier message and data rates may apply.

The Advertisement is not a solicitation or recommendation to buy securities of the advertised company. An offer to buy or sell securities can be made only by a disclosure document that complies with applicable securities laws and only in the states or other jurisdictions in which the security is eligible for sale. The Advertisement is not a disclosure document. The Advertisement is only a favorable snapshot of unverified information about the advertised company. An investor considering purchasing the securities, should always do so only with the assistance of his legal, tax and investment advisors. Investors should review with his or her investment advisor, tax advisor or attorney, if and to the extent available, any information concerning a potential investment at the web sites of the U.S. Securities and Exchange Commission the SEC at www.sec.gov the Financial Industry Regulatory Authority the FINRA at www.FINRA.org, and relevant State Securities Administrator website and the OTC Markets website at www.otcmarkets.com. The Publisher cautions investors to read the SEC advisory to investors concerning Internet Stock Fraud at www.sec.govconsumercyberfr.htm, as well as related information published by the FINRA on how to invest carefully. Investors are responsible for verifying all information in the Advertisement. As an advertiser, we do not verify any information we publish. The Advertisement should not be considered true or complete.

The Publisher does not offer investment advice or analysis, and the Publisher further urges you to consult your own independent tax, business, financial and investment advisors concerning any investment you make in securities particularly those quoted on the OTC Markets. Investing in securities is highly speculative and carries an extremely high degree of risk. You could lose your entire investment if you invest in any company mentioned in the Advertisement. You acknowledge that we are not an investment advisory service, a broker-dealer or an investment adviser and we are not qualified to act as such. You acknowledge that you will consult with your own independent, tax, financial andor legal advisers regarding any decisions as to any company mentioned here. We have not determined if the Advertisement is accurate, correct or truthful. The Advertisement is compiled from publicly available information, which include, but are not limited to, no cost online research, magazines, newspapers, reports filed with the SEC or information furnished by way of press releases. Because all information relied upon by us in preparing an advertisement about an issuer comes from a public source, it is not reliable, and you should not assume it is accurate or complete.

Owners and operators of the Publisher have been compensated twenty five thousand dollars by bank wire transfer on 32321 for the distribution of this advertisement about ATNM dated 32421. Previously, owners and operators of the Publisher have been compensated twenty five thousand dollars by bank wire transfer on 12420 for the distribution of a prior advertisement about ATNM. Previously, owners and operators of the Publisher have been compensated fifteen thousand dollars by bank wire transfer on 102920 for the distribution of a prior advertisement about ATNM. Previously, owners and operators of the Publisher have been compensated twenty five thousand dollars by bank wire transfer on 101920 for the distribution of a prior advertisement about ATNM. Prior to this period, at the time of publication, we disclosed our compensation for the distribution of advertisements about ATNM. The Publisher and its owners and operators hold no stocks or bonds in companies discussed in the Advertisement. Owners and operators of the Publisher own several newsletters, therefore you may receive multiple publications and emails featuring companies at different or the same time.

You are receiving this reportrelease because you subscribed to receive it at our website or through a third-party site. All our newsletters include an unsubscribe link, and you can remove yourself at any time from our newsletters by clicking on that unsubscribe link. You can also contact us at infoLionStockAlerts.com to change your information at any time. By your subscription to our profiles, the viewing of this profile andor use of our website, you have agreed and acknowledged the terms of our full disclaimer and privacy policy which can be viewed at the following link

www.LionStockAlerts.comDisclaimer and www.LionStockAlerts.comPrivacy-Policy

By accepting the Advertisement, you agree and acknowledge that any hyperlinks to the website of 1 a client company, 2 the party issuing or preparing the information for the company, or 3 other information contained in the Advertisement is provided only for your reference and convenience. The advertiser is not responsible for the accuracy or reliability of these external sites, nor is it responsible for the content, opinions, products or other materials on external sites or information sources. If you use, act upon or make decisions in reliance on information contained in any disseminated reportrelease or any hyperlink, you do so at your own risk and agree to hold us, our officers, directors, shareholders, affiliates and agents harmless. You acknowledge that you are not relying on the Publisher, and we are not liable for, any actions taken by you based on any information contained in any disseminated email or hyperlink.

Our records indicate that . requested and confirmed to be added to LionStockAlerts.com on July 23, 2019.

6020 Bent Pine Drive
Orlando FL 32828
USA